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Breast cancer (BC) is the most common type of cancer in
female, including Portugal, where this disease presents the
highest incidence and mortality rates [1]. BC risk factors,
like prolonged exposure to estrogen and/or ionizing radi-
ation, BRCA1, BRCA2, TP53, ATM and CHEK2 mutations
[2, 3], are related with an increased chance of DNA dam-
age, acting as initiators of cellular alterations. DNA repair
pathways are critical processes in order to maintain gen-
ome integrity. Therefore, genetic polymorphisms in DNA
repair genes are common events [4]. We previously
showed correlations of some of these genetic variations, as
XRCC1 Arg399Gln, RAD51 5’UTR G135C and XRCC3
Thr241Met, with changeable BC susceptibility [5].
In the present study, we aimed to investigate the pos-
sible correlations between DNA repair polymorphisms
with BC clinico-pathological phenotypes, identifying sub-
groups of patients according to their genetic background.
We analysed DNA from 165 BC patients, including 33
unrelated family history (FH) and 132 sporadic BC cases
from Surgical Departments of S. Joa˜o Hospital and the
Oncology Portuguese Institute, at Porto. All participants
provided informed consent. Patients presented a mean age
of 51.01 years (standard deviation (SD) ± 12.68).
We determined XRCC1 Arg399Gln, RAD51 5’0UTR
G135C and XRCC3 Thr241Met genotypes by PCR-RFLP
technique, as previously described [5]. Chi-square (v2 test)
analysis was used to compare different variables. Logistic
regression analysis was applied to calculate the adjusted p
value for age and FH in identification of subgroups of
patients according to genotypes. The Kaplan-Meier method
was used to estimate overall survival (OS). OS was defined
as minimal 60 months follow-up, from clinical diagnosis
until death or censorship (were alive at the end of the
follow-up time period). Differences on OS were obtained
by Log Rank test.
The correlation of the analysed DNA repair poly-
morphisms with some clinical-pathological features is
presented in Table 1. According to our results, XRCC1
Gln/Gln genotype seems to be associated with less
aggressive tumors, since this genotype was correlated
with well differentiated tumors (p = 0.022 adjusted for
age and BC FH, using logistic regression analysis).
Deficient efficiency of the XRCC1 protein has been
described in XRCC1 Gln399 variant [6, 7]. Furthermore,
repair of more complex base lesions [8, 9, 10] by base
excision repair (BER) pathway can potentially convert
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non-lethal lesion into lethal double strand breaks [11,
12]. Thus, deficiency in BER, by low efficiency of
XRCC1, may actually reflect a well differentiated nature
of the tumor cells in less aggressive tumors, since less
lethal lesions are produced.
We also observed that RAD51 C135 genotypes show a
relationship with more aggressive tumors and also with a
poorer OS, since we found a significant association of
RAD51 C135 genotypes with moderate to poor differenti-
ated grade (p = 0.011, adjusted for age and BC FH, using
logistic regression analysis). Additionally, assessment of
OS demonstrated that patients with RAD51 C135 geno-
types (102.87 months mean OS) presented a poorer sur-
vival compared with other genotype (136.36 months mean
OS) (Fig. 1). These results can be explained by the location
of this polymorphism in the untranslated region, may be
affecting mRNA stability and/or translation efficiency,
leading to altered RAD51 protein levels [13]. Thus,
RAD51, the key factor of homologous recombination
process, can disturb the activity of the multi protein DNA
repair complex, including BRCA1, BRCA2 and XRCC3,
contributing to high levels of genetic instability [14], and
as a result, being correlated with more aggressive breast
tumors and poor survival.
We had previously showed XRCC1 Arg399Gln and
RAD51 50UTR G135C as important polymorphism to pre-
dict breast cancer risk [5]. According to the present results,
we clearly underlie the role of these same polymorphisms
in the prediction of breast tumor aggressiveness and
patients’ survival.
Table 1 Correlation between DNA repair polymorphisms and clinical pathological parameters in Portuguese breast cancer patients
Parameters XRCC1 Arg399Gln RAD51 G135C XRCC3 Thr241Met
Gln/Gln Others GC or CC GG Met/Met Others
Histological Type
Invasive ductal 23 (92.0) 115 (86.5) 32 (91.4) 113 (86.9) 23 (88.5) 120 (88.2)
Invasive lobular 0 (0.0) 3 (2.3) 0 (0.0) 3 (2.3) 1 (3.8) 2 (1.5)
Others 2 (8.0) 15 (11.3) 3 (8.6) 14 (2.3) 2 (7.7) 14 (10.3)
P value 0.654 0.606 0.665
Histological Grade
I 5 (23.8) 8 (7.1) 6 (18.2) 9 (8.3) 1 (4.0) 14 (12.4)
II 6 (28.6) 61 (54.0) 21 (63.6) 51 (47.2) 11 (44.0) 57 (50.4)
III 10 (47.6) 44 (38.9) 6 (18.2) 48 (44.4) 13 (52.0) 42 (37.2)
P value 0.021a 0.017b 0.269
Axillary lymph node status
Negative 10 (41.7) 52 (40.0) 12 (40.0) 54 (41.5) 8 (32.0) 57 (43.5)
Positive 14 (58.3) 78 (60.0) 18 (60.0) 76 (58.5) 17 (68.0) 74 (56.5)
P value 0.878 0.877 0.285
Oestrogen receptor status
Negative 1 (33.3) 9 (31.0) 2 (28.6) 7 (25.9) 1 (33.3) 8 (27.6)
Positive 2 (66.7) 20 (69.0) 5 (71.4) 20 (74.1) 2 (66.7) 21 (72.4)
P value 0.935 0.888 0.833
Survival status at last follow-up
Death 3 (15.0) 13 (12.5) 2 (8.3) 15 (14.0) 1 (4.0) 16 (15.4)
Alive 17 (85.0) 91 (87.5) 22 (91.7) 92 (86.0) 24 (96.0) 88 (84.6)
P value 0.760 0.454 0.131
Recurrence at last follow-up
No 14 (77.8) 74 (82.2) 19 (86.4) 74 (80.4) 20 (87.0) 72 (80.0)
Yes 4 (22.2) 16 (17.8) 3 (13.6) 18 (19.6) 3 (13.0) 18 (20.0)
P value 0.658 0.519 0.444
a p value = 0.022, adjusted for age and history family of breast cancer to compare the influence of different genotypes in histological grade (I vs
II/III grade), using logistic regression analysis
b p value = 0.011, adjusted for age and history family of breast cancer to compare the influence of different genotypes in histological grade (I/II
vs III grade), using logistic regression analysis
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Fig. 1 Kaplan-Meier overall survival curve in breast cancer patients
relating with RAD51 G135C polymorphism. Log-rank test for
statistical analysis
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